Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naloxegol
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Naloxegol is a peripherally acting μ-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It is a PEGylated derivative of α-naloxol, designed to selectively block opioid receptors in the gastrointestinal tract without affecting central analgesia. The pegylation restricts its action to peripheral tissues by preventing significant penetration across the blood-brain barrier. Naloxegol was developed by AstraZeneca and licensed from Nektar Therapeutics. It was approved by the FDA in 2014 for use in adult patients who have been taking opioids for at least four weeks[3][5][1].
- Brand names
- MovantikMoventig
- Other names
- PEGylated naloxolα-naloxol PEGylated derivative
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on naloxegol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naloxegol.